TORONTO, June 16, 2009 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported that TF2, a proprietary pretargeting antibody, produced tumor-specific PET imaging and prolonged survival in a human colorectal cancer model. Results from two studies were presented at the 56th annual meeting of the Society of Nuclear Medicine.
